Immatics NV stock (NL0015255052): ASCO data spotlight PRAME cell therapy as Nasdaq shares hover around 11 USD

Immatics NV, listed on Nasdaq in the United States under the ticker IMTX, is back in focus after the company presented detailed Phase 1 data for its PRAME-targeting cell therapy anzu-cel (IMA203) at the 2026 ASCO Annual Meeting, underlining durable clinical activity in metastatic melanoma according to an Immatics communication as of 05/30/2026.Investing News as of 05/30/2026

The Germany-rooted, Netherlands-incorporated biotech reported that a one-time infusion of anzu-cel led to rapid, deep and durable systemic anti-tumor activity in metastatic PD-1-relapsed cutaneous melanoma and metastatic uveal melanoma, with a confirmed overall response rate of 56%, median duration of response of 14.6 months, median progression-free survival of 6.1 months and median overall survival of 16.2 months at the data cut-off, according to the same ASCO update as of 05/30/2026.Business Insider as of 05/30/2026

As of 05/29/2026, Immatics stock closed at 11.51 USD on Nasdaq, with extended-hours trading at 11.75 USD later that day, leaving the company outside major U.S. indices but firmly within the country’s biotech universe according to MarketBeat price data as of 05/29/2026.MarketBeat as of 05/29/2026

In Germany, the shares are also traded on platforms such as Tradegate, giving euro-based investors an additional access route to the Nasdaq-listed equity, though liquidity and spreads can differ from the U.S. home market.

The ASCO presentation emphasized that anzu-cel induced systemic anti-tumor activity across multiple metastatic sites, including difficult-to-treat locations such as liver, lung, lymph nodes, abdomen and skin, and that 42% of patients in the study achieved deep responses of at least 50% tumor reduction, based on the company’s clinical dataset as of 05/30/2026.Investing News as of 05/30/2026

The same update reported a progression-free survival rate of 55% at six months and 37% at 12 months, with overall survival rates of 70% at 12 months and 46% at 24 months, which are closely watched clinical indicators for oncology investors following the stock in the United States and abroad as of 05/30/2026.Business Insider as of 05/30/2026

The stock’s latest price levels and the newly disclosed Phase 1 details form the core of today’s news flow for Immatics NV as the company continues to advance a pipeline centered on T-cell receptor-based therapeutics in its German research hubs while maintaining its Dutch legal seat and U.S. equity listing.

As of: 02/02/2026

By the editorial team - specialized in equity coverage.

Immatics NV: core business model

Immatics NV concentrates on discovering and developing T-cell receptor-based immunotherapies that target cancer-specific antigens like PRAME, aiming to convert its research collaborations and eventual product approvals into recurring revenue streams.

Latest quarterly results for Immatics NV at a glance

For the latest reported quarter, Immatics has continued to post operating losses as it funds multiple early- and mid-stage clinical programs, a pattern consistent with development-stage biotech peers operating on Nasdaq. According to GuruFocus data as of 05/31/2026 for IMTX, the company’s market capitalization stood at around 1.57 billion USD, with a solid financial strength score of 8 out of 10, underlining that liquidity and balance sheet metrics are viewed as comparatively robust for a loss-making biotech at this stage.GuruFocus as of 05/31/2026

The same GuruFocus snapshot describes a GF Score of 61 out of 100 for Immatics as of 05/31/2026, indicating a moderate overall performance assessment on metrics such as profitability, growth and momentum, and investors following IMTX on U.S. and German trading venues often juxtapose these quantitative readings with the qualitative upside potential embedded in the company’s oncology pipeline.GuruFocus as of 05/31/2026

Conclusion

The latest ASCO 2026 Phase 1 data for anzu-cel place Immatics NV’s PRAME-targeted approach at the center of investor attention, with durable responses and survival outcomes now backed by longer follow-up in metastatic melanoma. At the same time, the company’s most recent quarterly profile shows it remains a development-stage biotech with solid balance sheet indicators but ongoing losses, a typical setup for a clinical-stage Nasdaq biotech that makes future cash flows highly dependent on trial progress. For IMTX, the combination of clinical readouts and financial resilience will likely shape how U.S. and European investors reassess risk and opportunity over the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.